



# TOXGURUKUL FOUNDATION PRESENTS

## 'ToxGurukul Webinar series'

**Title:**  
**Fundamentals of Pharmacokinetics**

**Date:** Saturday 08<sup>th</sup> Aug. 2020

**Time:** 8.00 pm. Indian Standard Time

**Duration:** 1.5 hours (1 hr + 30 min. Q&A)

**Registration link:** [Click here](#)

**Registration Fee:** 300 INR / \$10

**Payment link:** [Click here](#) for INR;  
[Click here](#) for \$

**Registration closing date:**  
07<sup>th</sup> Aug, 2020, at 12:00 pm IST, subjected to seats availability.

### Registration Procedure:


1. Register by clicking on registration link
2. You will receive a payment pending mail. Complete payment from link provided in mail or directly from payment links provided above.
3. You will receive a registration confirmation mail within 48 hours of payment

**Course Moderator:**

**Dr. Varun Ahuja** MSc, PhD, DABT, ERT

**For queries:** [toxgurukul.india@gmail.com](mailto:toxgurukul.india@gmail.com)

**Speaker:**  
**Dr. Gerhard Gross,**  
Owner, GG Pharma consultancy,  
Germany



Dr. Gerhard Gross (MSc, PhD) has worked at several senior positions in the pharmaceutical industry, including Department Head of ADME at Novartis, Head DvDMPK AP at AstraZeneca as well as Section Director ADME at AstraZeneca UK, Global Discipline Leader in ADME and Head of Drug Metabolism department at Lundbeck A/S in Copenhagen. He was also a member of the scientific advisory board of Entomopharm and a guest lecturer at the university of Copenhagen. In AstraZeneca he was establishing a transporter group, an outsourcing group and a biomarker group. He led a cross functional team within AstraZeneca to elaborate an internal strategy for the new FDA MIST guideline. At Lundbeck, he established the companies strategy for transporter and reactive metabolites, as well as strategically aligning the interface between discovery DMPK and development. He has been a key player in the development and registration of numerous drugs during his work for Novartis, e.g. Gilevec, Everolimus, Exjade, Myfortic, Rasilez, Zelmec and Zoledronate. He holds several patents for Gilevec, Exjade and Rasilez. There he was also responsible for the DMPK part of filing Nalmefene and also involved in the filing of Clobazam.

**Target audience:** Professionals from CROs, Pharmaceutical/Chemical/Medical device/Cosmetics/Personal care products Industry, Regulatory/Forensic/Environmental scientists, Pathologists, Academia (Faculty and research scholars e.g. MBBS, MPharma, MSc, PhD, RAs, JRFs/SRFs from any stream of pharmacological/ toxicological research).

**Sponsors willing to contribute financially to cover the cost of webinar, please contact:**

**Dr. Mukul Pore** MSc, DABT, ERT (President): 9822024836

**Dr. K.S. Rao** MSc, PhD, DABT (Patron): 7337830074